June 1, 2022
In this webinar Dr. Jan Hellemans, CTO and co-founder of Biogazelle, a CellCarta company, describes the intrinsic potential of droplet digital PCR (ddPCR) in clinical research for three different applications:
TO VIEW THE WEBINAR, CLICK HERE
Since becoming commercially available in 2011, digital PCR (dPCR) has been gaining in popularity as it enables nucleic acid quantification with superior accuracy and precision compared to quantitative PCR (qPCR). In brief, the technology consists of the following steps:
With data acquisition taking place at the end of the reaction, and since absolute concentrations can be determined, data can be easily interpreted and compared across different samples and experiments, especially in a clinical setting. Additionally, dPCR doesn’t suffer from the inherent complications of qPCR that result from the requirement of a standard curve and excels in the quantification of low abundant genes or small differences.